Tumor-associated macrophages promote resistance of hepatocellular carcinoma cells against sorafenib by activating CXCR2 signaling

Tumor-associated macrophages promote resistance of hepatocellular carcinoma cells against sorafenib by activating CXCR2 signaling

Abstract Background Sorafenib (SOR) is the first line treatment for advanced hepatocellular carcinoma (HCC), but resistance develops frequently. Tumor-associated macrophages (TAMs) have been reported to affect the progression of HCC. We therefore aimed to study the role of TAMs in promoting SOR resi...

Full description

Bibliographic Details
Main Authors: Hao-Chen Wang, Lin-Ya Haung, Chih-Jung Wang, Ying-Jui Chao, Ya-Chin Hou, Chia-Jui Yen, Yan-Shen Shan
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Journal of Biomedical Science
Subjects:
Hepatocellular carcinoma
Sorafenib resistance
Tumor-associated macrophage
CXCR2
CXCL1
CXCL2
Online Access:https://doi.org/10.1186/s12929-022-00881-4

Internet

https://doi.org/10.1186/s12929-022-00881-4

Similar Items